Levosimendan: A new option in acute cardiac failure

EMA - Emergency Medicine Australasia

Volumn 18, Issue 5-6, 2006, Pages 505-509

  Holley, Anthony David ^a   Ziegenfuss, Marc ^b  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b THE PRINCE CHARLES HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; DRUG METABOLITE; LEVOSIMENDAN; N [4 (1,4,5,6 TETRAHYDRO 4 METHYL 6 OXO 3 PYRIDAZINYL)PHENYL]ACETAMIDE; OR 1855; OXYGEN; PHOSPHODIESTERASE III INHIBITOR; PLACEBO; TROPONIN C; UNCLASSIFIED DRUG;

CALCIUM BLOOD LEVEL; CARDIOGENIC SHOCK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; COST EFFECTIVENESS ANALYSIS; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG UTILIZATION; HEADACHE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPOTENSION; IN VITRO STUDY; INOTROPISM; NAUSEA; OXYGEN CONSUMPTION; PRIORITY JOURNAL; REVIEW; VOMITING;

BIOLOGICAL AVAILABILITY; CARDIOTONIC AGENTS; HEART FAILURE, CONGESTIVE; HUMANS; HYDRAZONES; PYRIDAZINES; RANDOMIZED CONTROLLED TRIALS;

EID: 33750475576     PISSN: 17426731     EISSN: 17426723     Source Type: Journal    
DOI: 10.1111/j.1742-6723.2006.00871.x     Document Type: Review

References (25)

1. Sharma M, Teerlink JR. A rational approach for the treatment of acute heart failure: current strategies and future options. Curr. Opin. Cardiol. 2004; 19: 254-63.
2. Nieminen MS, Akkila J, Hasenfuss G et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J. Am. Coll. Cardiol. 2000; 36: 1903-12.
3. Cleland JG, McGowan J. Levosimendan: a new era for inodilator therapy for heart failure? Curr. Opin. Cardiol. 2002; 17: 257-65.
4. Kaheinen P, Pollesello P, Levijoki J et al. Levosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium channels. J. Cardiovasc. Pharmacol. 2001; 37: 367-74. Important basic research elucidating the mechanism of the vasodilator effects of levosimendan.
5. Pataricza J, Hohn J, Petri A et al. Comparison of the vasorelaxing effect of cromakalim and the new inodilator, levosimendan, in human isolated portal vein. J. Pharm. Pharmacol. 2000; 52: 213-17.
6. Lilleberg J, Nieminen MS, Akkila J et al. Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting. Eur. Heart J. 1998; 19: 660-8.
7. Haikala H, Kaheinen P, Levijoki J et al. The role of cAMP-and cGMP-dependent protein kinases in the cardiac actions of the new calcium sensitizer, levosimendan. Cardiovasc. Res. 1997; 34: 536-46.
8. Slawsky MT, Colucci WS, Gottlieb SS et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation 2000; 102: 2222-7.
9. Michaels AD, McKeown B, Kostal M et al. Effects of intravenous levosimendan on human coronary vasomotor regulation, left ventricular wall stress, and myocardial oxygen uptake. Circulation 2005; 111: 1504-9.
10. Sandell E-P, Hayha M, Antila S et al. Pharmacokinetics of levosimendan in healthy volunteers and patients with congestive heart failure. J. Cardiovasc. Pharmacol. 1995; 26 (Suppl. 1): 557-62.
11. Jonsson EN, Antila S, McFadyen L, Lehtonen L, Karlsson MO. Population pharmacokinetics of levosimendan in patients with congestive heart failure. Br. J. Clin. Pharmacol. 2003; 55: 544-51.
12. Sundberg S, Antila S, Scheinin H, Hayha M, Virtanen M, Lehtonen L. Integrated pharmacokinetics and pharmacodynamics of the novel calcium sensitizer levosimendan as assessed by systolic time intervals. Int. J. Clin. Pharmacol. Ther. 1998; 36: 629-35.
13. Antila S, Kivikko M, Lehtonen L et al. Pharmacokinetics of levosimendan and its circulating metabolites in patients with heart failure after an extended continuous infusion of levosimendan. Br. J. Clin. Pharmacol. 2004; 57: 412-15.
14. Antila S, Pesonen U, Lehtonen L et al. Pharmacokinetics of levosimendan and its active metabolite OR-1896 in rapid and slow acetylators. Eur. J. Pharm. Sci. 2004; 23: 213-22.
15. Kivikko M, Lehtonen L, Colucci WS. Sustained hemodynamic effects of intravenous levosimendan. Circulation 2003; 107: 81-6.
16. Poder P, Eha J, Sundberg S et al. Pharmacodynamics and pharmacokinetics of oral levosimendan and its metabolites in patients with severe congestive heart failure: a dosing interval study. J. Clin. Pharmacol. 2004; 44: 1143-50.
17. Moiseyev VS, Poder P, Andrejevs N et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur. Heart J. 2002; 23: 1422-32 18.
18. Steering Committee and Investigators of the Levosimendan Infusion versus Dobutamine (LIDO) Study. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomized doubleblind trial. Lancet 2002; 360: 196-202.
19. Packer M. REVIVE II trial investigators REVIVE II: multicenter placebo-controlled trial of levosimendan on clinical status in acutely decompensated heart failure. Circulation 2005; 112: 3363.
20. Mebazaa A, Packer M. The SURVIVE-W trial: comparison of dobutamine and levosimendan on survival in acute decompensated heart failure. Circulation 2005; 112: 3364.
21. Lehmann A, Lang J, Boldt J, Isgro F, Kiessling AH. Levosimendan in patients with cardiogenic shock undergoing surgical revascularization: a case series. Med. Sci. Monitor. 2004; 10: MT89-93.
22. Huang L, Weil MH, Tang, WC, Sun SJ, Wang JL. Comparison between dobutamine and levosimendan for management of post resuscitation myocardial dysfunction. Crit. Care Med. 2005; 33: 487-91.
23. Huang L, Weil MH, Sun S, Cammarata G, Cao L, Tang W. Levosimendan improves postresuscitation outcomes in a rat model of CPR. J. Lab. Clin. Med. 2005; 146: 256-61.
24. Kivikko M, Antila S, Eha J et al. Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure. J. Clin. Pharmacol. 2002; 42: 43-51.
25. Cleland JG, Takala A, Apajasalo M, Zethraeus N, Kobelt G. Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: an analysis based on the international LIDO trial. Eur. J. Heart Fail. 2003; 5: 101-8.